Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation

John P. Sinek, Sandeep Sanga, Xiaoming Zheng, Hermann B. Frieboes, Mauro Ferrari, Vittorio Cristini

Research output: Contribution to journalArticlepeer-review

69 Scopus citations

Abstract

In this paper, we investigate the pharmacokinetics and effect of doxorubicin and cisplatin in vascularized tumors through two-dimensional simulations. We take into account especially vascular and morphological heterogeneity as well as cellular and lesion-level pharmacokinetic determinants like P-glycoprotein (Pgp) efflux and cell density. To do this we construct a multi-compartment PKPD model calibrated from published experimental data and simulate 2-h bolus administrations followed by 18-h drug washout. Our results show that lesion-scale drug and nutrient distribution may significantly impact therapeutic efficacy and should be considered as carefully as genetic determinants modulating, for example, the production of multidrug-resistance protein or topoisomerase II. We visualize and rigorously quantify distributions of nutrient, drug, and resulting cell inhibition. A main result is the existence of significant heterogeneity in all three, yielding poor inhibition in a large fraction of the lesion, and commensurately increased serum drug concentration necessary for an average 50% inhibition throughout the lesion (the IC 50 concentration). For doxorubicin the effect of hypoxia and hypoglycemia ("nutrient effect") is isolated and shown to further increase cell inhibition heterogeneity and double the IC50, both undesirable. We also show how the therapeutic effectiveness of doxorubicin penetration therapy depends upon other determinants affecting drug distribution, such as cellular efflux and density, offering some insight into the conditions under which otherwise promising therapies may fail and, more importantly, when they will succeed. Cisplatin is used as a contrast to doxorubicin since both published experimental data and our simulations indicate its lesion distribution is more uniform than that of doxorubicin. Because of this some of the complexity in predicting its therapeutic efficacy is mitigated. Using this advantage, we show results suggesting that in vitro monolayer assays using this drug may more accurately predict in vivo performance than for drugs like doxorubicin. The nonlinear interaction among various determinants representing cell and lesion phenotype as well as therapeutic strategies is a unifying theme of our results. Throughout it can be appreciated that macroscopic environmental conditions, notably drug and nutrient distributions, give rise to considerable variation in lesion response, hence clinical resistance. Moreover, the synergy or antagonism of combined therapeutic strategies depends heavily upon this environment.

Original languageEnglish (US)
Pages (from-to)485-510
Number of pages26
JournalJournal of Mathematical Biology
Volume58
Issue number4-5
DOIs
StatePublished - Apr 2009

Keywords

  • In silico
  • Pharmacokinetics
  • Prediction
  • Simulation
  • Therapy

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • Applied Mathematics
  • Modeling and Simulation

Fingerprint

Dive into the research topics of 'Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation'. Together they form a unique fingerprint.

Cite this